Telix Pharmaceuticals Limited’s Price-to-Sales Ratio at a glance
Telix Pharmaceuticals Limited reports price-to-sales ratio of 10.4x for Dec 2024. The prior period recorded 6.4x (Dec 2023). Year over year the metric moved +4.01 (+62.6%). The rolling three-period average stands at 10.3x. Data last refreshed Dec 7, 2025, 2:51 AM.
Latest reading
10.4x · Dec 2024
YoY movement
+4.01 (+62.6%)
Rolling average
10.3x
Current Price-to-Sales Ratio
10.4x
+4.01
+62.6%
Rolling average
10.3x
Latest Value
10.4x
Dec 2024
YoY Change
+4.01
Absolute
YoY Change %
+62.6%
Rate of change
3-Period Avg
10.3x
Smoothed
Narrative signal
Telix Pharmaceuticals Limited’s price-to-sales ratio stands at 10.4x for Dec 2024. Year-over-year, the metric shifted by +4.01, translating into a +62.6% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-sales ratio shapes Telix Pharmaceuticals Limited's story
As of Dec 2024, Telix Pharmaceuticals Limited reports price-to-sales ratio of 10.4x. Track price-to-sales multiples to contextualize revenue-driven valuation swings and peer comparisons.
When to use price-to-sales
P/S is helpful for companies with slim or volatile profits. It shows how rich investors value each dollar of revenue.
Compare against industry norms
High-growth software firms command higher P/S ratios than retailers. Stack the metric versus sector averages to read sentiment.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.1%
Operating Margin
10.5%
Net Profit Margin
6.4%
Return on Equity
8.8%
Return on Assets
3.3%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Telix Pharmaceuticals Limited (TLX) FAQs
Answers tailored to Telix Pharmaceuticals Limited’s price-to-sales ratio profile using the latest Financial Modeling Prep data.
What is Telix Pharmaceuticals Limited's current price-to-sales ratio?
As of Dec 2024, Telix Pharmaceuticals Limited reports price-to-sales ratio of 10.4x. This reading reflects the latest filings and price data for TLX.
How is Telix Pharmaceuticals Limited's price-to-sales ratio trending year over year?
Year-over-year, the figure shifts by +4.01 (+62.6%). Pair this context with revenue growth and free cash flow signals to gauge momentum for TLX.
Why does price-to-sales ratio matter for Telix Pharmaceuticals Limited?
Price-to-sales compares market capitalization with revenue to assess valuation against top-line performance. For Telix Pharmaceuticals Limited, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Telix Pharmaceuticals Limited's price-to-sales ratio above its recent average?
Telix Pharmaceuticals Limited's rolling three-period average sits at 10.3x. Comparing the latest reading of 10.4x to that baseline highlights whether momentum is building or fading for TLX.
How frequently is Telix Pharmaceuticals Limited's price-to-sales ratio refreshed?
Data for TLX was last refreshed on Dec 7, 2025, 2:51 AM and updates automatically every 24 hours, keeping your valuation inputs current.